It is the CSMBS, with its generous fee-for-service benefit package, that is facing greatest
difficulties in containing costs, and presents threats to financial sustainability. Recent attempts at cost containment, e.g., through payments based on DRG and limitations on drug
reimbursements, seem to have, at least temporarily, halted rapid rises in spending.